A

Assembly Biosciences
D

ASMB

15.160
USD
-0.34
(-2.19%)
Pre Open
Volume
100
EPS
-6
Div Yield
-
P/E
-2
Market Cap
96,361,296
OverviewSignalsIdeasNews
Related Instruments
    ABBV
    ABBV
    -0.285
    (-0.16%)
    175.415 USD
    AMGN
    AMGN
    -2.07
    (-0.79%)
    261.29 USD
    BMY
    BMY
    -0.330
    (-0.58%)
    56.950 USD
    GILD
    GILD
    0.100
    (0.11%)
    92.670 USD
    I
    INO
    -0.03000
    (-1.64%)
    1.80000 USD
    LLY
    LLY
    11.09
    (1.44%)
    780.21 USD
    MRK
    MRK
    0.250
    (0.25%)
    98.410 USD
    N
    NVAX
    -0.13000
    (-1.49%)
    8.59000 USD
    PFE
    PFE
    0.005
    (0.02%)
    26.365 USD
    REGN
    REGN
    8.80
    (1.25%)
    711.40 USD
    More
News

Title: Assembly Biosciences

Sector: Healthcare
Industry: Biotechnology
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenueis generated from the HBV cure program.